Contact
searchSearch
HMP Global
Login

Recent News

News
Phase 3 IMpactMF Trial of Imetelstat Discontinued After Unfavorable Overall Survival Assessment
10/30/2026
Emily Estrada
The phase 3 IMpactMF trial of imetelstat in patients with JAK inhibitor-relapsed or refractory myelofibrosis has been discontinued after an independent Data Monitoring Committee determined that the study was unlikely to meet its primary...
The phase 3 IMpactMF trial of imetelstat in patients with JAK inhibitor-relapsed or refractory myelofibrosis has been discontinued after an independent Data Monitoring Committee determined that the study was unlikely to meet its primary...
The phase 3 IMpactMF trial of...
10/30/2026
Oncology
News
Cosibelimab Receives NCCN Category 2A Recommendation for Locally Advanced Cutaneous Squamous Cell Carcinoma
10/30/2026
Emily Estrada
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include...
10/30/2026
Oncology
News
Petosemtamab Plus Pembrolizumab Significantly Improves Overall Survival in Patients With Head and Neck Squamous Cell Carcinoma
10/30/2026
Emily Estrada
Results from the phase 3 LiGeR-HN1 trial demonstrated that petosemtamab plus pembrolizumab significantly improved overall survival and objective response compared with pembrolizumab alone in patients with PD-L1-positive recurrent or...
Results from the phase 3 LiGeR-HN1 trial demonstrated that petosemtamab plus pembrolizumab significantly improved overall survival and objective response compared with pembrolizumab alone in patients with PD-L1-positive recurrent or...
Results from the phase 3...
10/30/2026
Oncology
News
Relacorilant Plus Nab-Paclitaxel and Bevacizumab Demonstrates 59% Response Rate in Platinum-Resistant Ovarian Cancer
10/30/2026
Stephanie Holland
Results from the phase 2 BELLA trial demonstrated encouraging progression-free survival and response with relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer, with more pronounced activity among...
Results from the phase 2 BELLA trial demonstrated encouraging progression-free survival and response with relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer, with more pronounced activity among...
Results from the phase 2 BELLA...
10/30/2026
Oncology
News
Updated ASTRO Guidelines Expand Role of Hypofractionated Radiotherapy in Localized Prostate Cancer
10/30/2026
Stephanie Holland
Updated ASTRO clinical practice guidelines recommend moderate hypofractionated radiotherapy over conventional fractionation across all localized prostate cancer risk groups and expand the role of ultrahypofractionation, including stereotactic...
Updated ASTRO clinical practice guidelines recommend moderate hypofractionated radiotherapy over conventional fractionation across all localized prostate cancer risk groups and expand the role of ultrahypofractionation, including stereotactic...
Updated ASTRO clinical practice...
10/30/2026
Oncology
News
Real-World Study Demonstrates Clinical Activity of Lurbinectedin in Previously Treated Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from the phase 4 Jazz...
10/28/2026
Oncology
News
NETSARC+ Study Identifies Tumor Location and Size as Prognostic Factors in Patients With Desmoid Tumors
10/28/2026
Emily Estrada
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+...
10/28/2026
Oncology
News
G-CSF Prophylaxis Reduces Incidence of Febrile Neutropenia Without Compromising Chemoimmunotherapy Outcomes in Patients With Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from a multicenter,...
10/28/2026
Oncology
News
Tambotatug Pelitecan Significantly Improves Overall Survival in Patients With Relapsed Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
Results from the phase 3...
10/28/2026
Oncology
News
Oral Hypomethylating Agents Show Comparable Hematologic Toxicity to Intravenous Therapy in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia
10/28/2026
Emily Estrada
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter...
10/28/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use